The role of vascular endothelial growth factor as a potential therapy of psoriasis vulgaris: A literature review

Keyphrases

• Vascular Endothelial Growth Factor 100%
• Potential Therapy 100%
• Psoriasis Vulgaris 100%
• Psoriasis 60%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 60%
• Therapeutic Agents 40%
• Hypertension 40%
• Proteinuria 40%
• Vascular Endothelial Growth Factor Inhibitors 40%
• Angiogenesis 20%
• Interleukin-8 20%
• Monoclonal Antibody 20%
• Treatment Failure 20%
• Tumor Necrosis Factor-α 20%
• Therapeutic Target 20%
• Keratinocytes 20%
• Interleukin-17 (IL-17) 20%
• Systemic Administration 20%
• T Cells 20%
• Vascular Disease 20%
• Fusion Protein 20%
• Vascular Endothelial Growth Factor Receptor (VEGFR) 20%
• Therapeutic Efficacy 20%
• Long-term Treatment 20%
• Protein Receptor 20%
• Receptor Antagonist 20%
• Psoriasis Disease 20%
• Impaired Wound Healing 20%
• Effective Therapy 20%
• Bevacizumab 20%
• Long-term Efficacy 20%
• Angiogenic Factors 20%
• Psoriasis Therapy 20%
• Psoriasis Treatment 20%
• Treatment Toxicity 20%
• Psoriasis Management 20%
• Lesion Area 20%
• Poor Wound Healing 20%
• Psoriasis Pathogenesis 20%
• Side Effects of Therapy 20%
• PSORI-CM02 20%
• Angiopoietin 20%
• Receptor Tyrosine Kinase Inhibitor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Angiopoietin 12%

Medicine and Dentistry

• Angiopoietin 12%